Fitzgerald Quoted on Current State of Health Plan Subsidies
05 April 2017
HealthLeaders Magazine
Partner Kevin Fitzgerald was quoted in a HealthLeaders Magazine article, “Premiums Likely to Rise, More Insurers Will Leave Exchanges,” covering the uncertainty of subsidies, employee health benefits and viability of the individual market through the implementation of the Affordable Care Act under the Trump administration.
Fitzgerald explained that “uncertainty about whether ‘repeal and replace’ would pass in some form has merely been replaced by new uncertainty around cost-sharing reductions and profitability … without cost-sharing reduction payments, there will likely be no sustainable individual market.”
Fitzgerald explained that “uncertainty about whether ‘repeal and replace’ would pass in some form has merely been replaced by new uncertainty around cost-sharing reductions and profitability … without cost-sharing reduction payments, there will likely be no sustainable individual market.”
People
Related News
10 October 2024
In the News
Christopher King Highlights M&A Due Diligence Considerations
Foley & Lardner LLP partner Christopher King's comments on M&A due diligence at the Association of Corporate Counsel's annual meeting were highlighted in the Legal Dive article, "Can this marriage work? Legal tips for corporate M&A."
09 October 2024
In the News
Jason Mehta Weighs in on SEC Settlements, Clinical Research Fraud
Foley & Lardner LLP partner Jason Mehta commented on a recent health care litigation settlement with the U.S. Securities and Exchange Commission in the Clinical Trials Arena article, “Cassava Sciences: Phase III trials storm ahead amid controversy.”
08 October 2024
In the News
John Strom Assesses BIOSECURE ACT – 'Going to be tough to navigate'
Foley & Lardner LLP special counsel John Strom shared insight on the potential impact of the BIOSECURE ACT in the BioSpaces article, "WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow."